More phase III data coursed through the annual American Society of Clinical Oncology (ASCO) conference on Sunday, as Protagonist Therapeutics Inc. and Takeda Pharmaceutical Co. Ltd. led the charge with positive results for its potential blockbuster rusfertide in treating a rare leukemia.
New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was encouraged by the efficacy results. However, investors felt otherwise, as the stock lost about 20% of its value the day the initial results were released.
LIN28 is a family of RNA-binding proteins that regulate stem cell biology and pluripotency and are involved in oncogenesis through the interaction with tumor suppressor microRNA let-7. The expression of LIN28 leads to the loss of function of let-7, leading to tumorigenesis, and has been tied to tumor aggressiveness and poor survival in children with brain tumors.
The systemic virotherapy strategy involves not only the direct delivery of therapeutic payloads encoded by viruses to tumors, but also the modification of the tumor microenvironment, aiming to target both primary and metastatic lesions. At the ongoing American Society of Clinical Oncology (ASCO) meeting, researchers from Calidi Biotherapeutics Inc. reported the development of a novel approach using a selected and engineered tumor-selective strain of vaccinia virus.
Despite the advancement of AI and machine learning technologies and their incorporation into cancer treatment and drug development, a lack of trust and understanding of these new approaches is impeding care and treatment.
New and positive phase III cancer data for two monoclonal antibodies from two pharma giants opened the second day of the American Society of Clinical Oncology (ASCO) conference this past weekend.
More phase III data coursed through the annual American Society of Clinical Oncology (ASCO) conference on Sunday, as Protagonist Therapeutics Inc. and Takeda Pharmaceutical Co. Ltd. led the charge with positive results for its potential blockbuster rusfertide in treating a rare leukemia.
At the 61st American Society of Clinical Oncology (ASCO) Annual Meeting, multiple companies presented clinical trial data showing their drugs and devices helped patients with pancreatic cancer live longer or improve their ability to respond to treatment.
Preclinical findings have shown matrix metalloproteinase 7 (MMP-7) inhibition confers antifibrotic effects and thus, is a promising therapeutic strategy to treat idiopathic pulmonary fibrosis (IPF). Changchun Genescience Pharmaceutical Co. Ltd. has presented data on the siRNA technology-based MMP-7 inhibitor GenSciP117 for treating IPF.
Despite the advancement of AI and machine learning technologies and their incorporation into cancer treatment and drug development, a lack of trust and understanding of these new approaches is impeding care and treatment.
RSS
